journal
MENU ▼
Read by QxMD icon Read
search

PharmacoEconomics

journal
https://www.readbyqxmd.com/read/27873226/is-dimension-order-important-when-valuing-health-states-using-discrete-choice-experiments-including-duration
#1
Brendan Mulhern, Richard Norman, Paula Lorgelly, Emily Lancsar, Julie Ratcliffe, John Brazier, Rosalie Viney
BACKGROUND: Discrete choice experiments with duration (DCETTO) can be used to estimate utility values for preference-based measures, such as the EQ-5D-5L. For self-completion, the health dimensions are presented in a standard order. However, for valuation, this may result in order effects. Thus, it is important to understand whether health state dimension ordering affects values. The aim of this study was to examine the importance of dimension ordering on DCE values using EQ-5D-5L. METHODS: A choice experiment presenting two health profiles and a third immediate death option was developed...
November 21, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27873225/how-consistent-is-the-relationship-between-improved-glucose-control-and-modelled-health-outcomes-for-people-with-type-2-diabetes-mellitus-%C3%A2-a-systematic-review
#2
REVIEW
Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H Herman, Philip Clarke
BACKGROUND: There are an increasing number of studies using simulation models to conduct cost-effectiveness analyses for type 2 diabetes mellitus. OBJECTIVE: To evaluate the relationship between improvements in glycosylated haemoglobin (HbA1c) and simulated health outcomes in type 2 diabetes cost-effectiveness studies. METHODS: A systematic review was conducted on MEDLINE and EMBASE to collect cost-effectiveness studies using type 2 diabetes simulation models that reported modelled health outcomes of blood glucose-related interventions in terms of quality-adjusted life-years (QALYs) or life expectancy (LE)...
November 21, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27858368/valuing-meta-health-effects-for-use-in-economic-evaluations-to-inform-reimbursement-decisions-a-review-of-the-evidence
#3
REVIEW
Richard De Abreu Lourenco, Marion Haas, Jane Hall, Rosalie Viney
OBJECTIVE: This review explores the evidence from the literature regarding how meta-health effects (effects other than health resulting from the consumption of health care) are valued for use in economic evaluations. METHODS: A systematic review of the published literature (the EMBASE, MEDLINE, PsycINFO, CINAHL, EconLit and SocINDEX databases were searched for publications in March 2016, plus manual searching) investigated the associations between study methods and the resulting values for meta-health effects estimated for use in economic evaluations...
November 17, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27848220/evolocumab-for-treating-primary-hypercholesterolaemia-and-mixed-dyslipidaemia-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#4
REVIEW
Christopher Carroll, Paul Tappenden, Rachid Rafia, Jean Hamilton, Duncan Chambers, Mark Clowes, Paul Durrington, Nadeem Qureshi, Anthony S Wierzbicki
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin (HMG-CoA reductase inhibitor) with or without ezetimibe, or in combination with ezetimibe (without statin therapy), in adult patients with primary hypercholesterolaemia (which includes mixed dyslipidaemia), for whom statins do not provide optimal control of their low-density lipoprotein cholesterol (LDL-C) levels and/or for whom statins are contraindicated or not tolerated...
November 16, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27848219/the-valuation-of-informal-care-in-cost-of-illness-studies-a-systematic-review
#5
REVIEW
Juan Oliva-Moreno, Marta Trapero-Bertran, Luz Maria Peña-Longobardo, Raúl Del Pozo-Rubio
BACKGROUND: There is a growing interest in incorporating informal care in cost-of-illness studies as a relevant part of the economic impact of some diseases. OBJECTIVE: The aim of this paper was to review the recent literature valuating the costs of informal care in a group of selected diseases from 2005 to 2015. METHODS: We carried out a systematic review on the economic impact of informal care, focusing on six selected diseases: arthritis or osteoarthritis, cancer, dementia, mental diseases, multiple sclerosis and stroke...
November 15, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27838913/validation-of-the-economic-and-health-outcomes-model-of-type-2-diabetes-mellitus-echo-t2dm
#6
Michael Willis, Pierre Johansen, Andreas Nilsson, Christian Asseburg
BACKGROUND: The Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM) was developed to address study questions pertaining to the cost-effectiveness of treatment alternatives in the care of patients with type 2 diabetes mellitus (T2DM). Naturally, the usefulness of a model is determined by the accuracy of its predictions. A previous version of ECHO-T2DM was validated against actual trial outcomes and the model predictions were generally accurate. However, there have been recent upgrades to the model, which modify model predictions and necessitate an update of the validation exercises...
November 12, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27838912/emergent-challenges-in-determining-costs-for-economic-evaluations
#7
Josephine C Jacobs, Paul G Barnett
This paper describes methods of determining costs for economic evaluations of healthcare and considers how cost determination is being affected by recent developments in healthcare. The literature was reviewed to identify the strengths and weaknesses of the four principal methods of cost determination: micro-costing, activity-based costing, charge-based costing, and gross costing. A scoping review was conducted to identify key trends in healthcare delivery and to identify costing issues associated with these changes...
November 12, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27832461/weighing-clinical-evidence-using-patient-preferences-an-application-of-probabilistic-multi-criteria-decision-analysis
#8
Henk Broekhuizen, Maarten J IJzerman, A Brett Hauber, Catharina G M Groothuis-Oudshoorn
The need for patient engagement has been recognized by regulatory agencies, but there is no consensus about how to operationalize this. One approach is the formal elicitation and use of patient preferences for weighing clinical outcomes. The aim of this study was to demonstrate how patient preferences can be used to weigh clinical outcomes when both preferences and clinical outcomes are uncertain by applying a probabilistic value-based multi-criteria decision analysis (MCDA) method. Probability distributions were used to model random variation and parameter uncertainty in preferences, and parameter uncertainty in clinical outcomes...
November 10, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27798809/a-review-of-us-drug-costs-relevant-to-medicare-medicaid-and-commercial-insurers-post-affordable-care-act-enactment-2010-2016
#9
REVIEW
Jacquelyn McRae, F Randy Vogenberg, Silky Webb Beaty, Elizabeth Mearns, Stefan Varga, Laura Pizzi
Since passage of the Affordable Care Act (ACA) in 2010, US stakeholders are increasingly being held accountable for the value of healthcare services and drugs administered to patients. Pharmacoeconomic analyses offer one method of demonstrating a product's value, yet there is a lack of resources specific to US drug costs relevant to each stakeholder. The aim of this study was to review current US drug costs (post-ACA). A literature review aimed at finding evidence on outpatient prescription drug costs was performed using the following sources: PubMed, governmental agencies, news websites, the Academy of Managed Care Pharmacy (AMCP) website, and Google Scholar...
October 31, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27798808/economic-evaluation-in-duchenne-muscular-dystrophy-model-frameworks-for-cost-effectiveness-analysis
#10
Erik Landfeldt, Lars Alfredsson, Volker Straub, Hanns Lochmüller, Katharine Bushby, Peter Lindgren
BACKGROUND: Several treatments are on the horizon for Duchenne muscular dystrophy (DMD), a terminal orphan disease. In many jurisdictions, decisions regarding pricing and reimbursement of these health technologies comprise evidence of value for money. OBJECTIVE: The objective of this study was to develop a cost-effectiveness model based on the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT), a new rating scale created specifically to measure disease progression in clinical practice and trials and model DMD in economic evaluations, and compare it with two alternative model structures...
October 31, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27787744/simulation-modelling-in-ophthalmology-application-to-cost-effectiveness-of-ranibizumab-and-aflibercept-for-the-treatment-of-wet-age-related-macular-degeneration-in-the-united-kingdom
#11
Lindsay Claxton, Robert Hodgson, Matthew Taylor, Bill Malcolm, Ruth Pulikottil Jacob
BACKGROUND: Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions...
October 27, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27785772/a-systematic-review-of-cardiovascular-outcomes-based-cost-effectiveness-analyses-of-lipid-lowering-therapies
#12
REVIEW
Ching-Yun Wei, Ruben G W Quek, Guillermo Villa, Shravanthi R Gandra, Carol A Forbes, Steve Ryder, Nigel Armstrong, Sohan Deshpande, Steven Duffy, Jos Kleijnen, Peter Lindgren
BACKGROUND: Previous reviews have evaluated economic analyses of lipid-lowering therapies using lipid levels as surrogate markers for cardiovascular disease. However, drug approval and health technology assessment agencies have stressed that surrogates should only be used in the absence of clinical endpoints. OBJECTIVE: The aim of this systematic review was to identify and summarise the methodologies, weaknesses and strengths of economic models based on atherosclerotic cardiovascular disease event rates...
October 27, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27785771/pharmacoeconomic-considerations-in-treating-actinic-keratosis-an-update
#13
REVIEW
Spencer M Vale, Dane Hill, Steven R Feldman
Actinic keratosis is one of the most common dermatological diagnoses worldwide, especially among the elderly, fair-skinned, and immunocompromised, and is associated with a risk of transformation to skin cancer. With actinic keratosis and skin cancer prevalence increasing as the aged population expands in the US, optimizing treatment strategies may produce cost savings for the healthcare system. Since the time of our last review in 2008, investigation of the economic considerations in treating actinic keratosis has advanced...
October 27, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27785770/measuring-the-value-of-pharmaceuticals-in-the-us-health-system
#14
EDITORIAL
Surrey M Walton, Anirban Basu, John Mullahy, Samuel Hong, Glen T Schumock
No abstract text is available yet for this article.
October 27, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27778240/economic-evaluations-of-pharmaceuticals-granted-a-marketing-authorisation-without-the-results-of-randomised-trials-a-systematic-review-and-taxonomy
#15
Anthony J Hatswell, Nick Freemantle, Gianluca Baio
BACKGROUND: Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo). OBJECTIVE: To identify and develop a taxonomic account of economic modelling approaches for pharmaceuticals licensed without RCT data. METHODS: We searched PubMed, the websites of UK health technology assessment bodies and the International Society for Pharmacoeconomics and Outcomes Research Scientific Presentations Database for assessments of treatments granted a marketing authorisation by the US Food and Drug Administration or European Medicines Agency from January 1999 to May 2014 without RCT data (74 indications)...
October 24, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27770303/cabazitaxel-for-hormone-relapsed-metastatic-prostate-cancer-previously-treated-with-a-docetaxel-containing-regimen-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#16
Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Hamilton, Duncan Chambers, Mark Clowes, John Graham, M Satish Kumar
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures cabazitaxel (Jevtana(®), Sanofi, UK) to submit evidence for the clinical and cost effectiveness of cabazitaxel for treatment of patients with metastatic hormone-relapsed prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen. The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
October 22, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27752999/azacitidine-for-treating-acute-myeloid-leukaemia-with-more-than-30%C3%A2-bone-marrow-blasts-an-evidence-review-group-perspective-of-a-national-institute-for-health-and-care-excellence-single-technology-appraisal
#17
Irina A Tikhonova, Martin W Hoyle, Tristan M Snowsill, Chris Cooper, Joanna L Varley-Campbell, Claudius E Rudin, Ruben E Mujica Mota
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of azacitidine (Celgene) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of acute myeloid leukaemia with more than 30 % bone marrow blasts in adults who are not eligible for haematopoietic stem cell transplantation, as part of the NICE's Single Technology Appraisal process. The Peninsula Technology Assessment Group was commissioned to act as the Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company's submission to NICE...
October 17, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27752998/systematic-review-of-the-cost-effectiveness-of-insulin-analogues-in-type-1-and-type-2-diabetes-mellitus
#18
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan, Nathorn Chaiyakunapruk
BACKGROUND: Insulin analogues have a pharmacokinetic advantage over human insulin and are increasingly used to treat diabetes mellitus. A summary of their cost effectiveness versus other available treatments was required. OBJECTIVE: Our objective was to systematically review the published cost-effectiveness studies of insulin analogues for the treatment of patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). METHODS: We searched major databases and health technology assessment agency reports for economic evaluation studies published up until 30 September 2015...
October 17, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27722894/modeling-treatment-sequences-in-pharmacoeconomic-models
#19
Ying Zheng, Feng Pan, Sonja Sorensen
As the number of interventions available in a therapeutic area increases, the relevant decision questions in health technology assessment (HTA) expand to compare treatment sequences instead of discrete treatments and identify optimal sequences or position for a particular treatment in a sequence. The objective of this work was to review approaches used to model treatment sequences and provide practical guidance on conceptualizing whether and how to model sequences in health economic models. Economic models including treatment sequencing assessed by the National Institute for Health and Care Excellence were reviewed, as these assessments generally provide both policy relevance and comprehensive model detail...
October 8, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27663572/cost-effectiveness-of-naloxegol-for-opioid-induced-constipation-in-the-uk
#20
Richard Lawson, James Ryan, Frederic King, Jo Wern Goh, Eszter Tichy, Kevin Marsh
BACKGROUND AND OBJECTIVES: Opioid-induced constipation (OIC) is the most common adverse effect reported in patients receiving opioids to manage pain. Initial treatment with laxatives provides inadequate response in some patients. Naloxegol is a peripherally acting µ-opioid receptor antagonist used to treat patients with inadequate response to laxative(s) (laxative inadequate responder [LIR]). A cost-effectiveness model was constructed from the UK payer perspective to compare oral naloxegol 25 mg with placebo in non-cancer LIR patients receiving opioids for chronic pain, and a scenario analysis of naloxegol 25 mg with rescue laxatives compared with placebo with rescue laxatives in the same patient population...
September 23, 2016: PharmacoEconomics
journal
journal
31126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"